参考文献
1.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines): Non-Small Cell Lung Cancer Version 2.2019 -November 21,2018.
2.American Joint Committee on Cancer(AJCC)Cancer Staging System(8th ed.,2017).
3.Johnson DH,Schiller JH,Bunn PA, Recent clinical advances in lung cancer management.J Clin Oncol 2014, 32:973-982.
4.Forde PM,Ettinger DS.Targeted therapy for non-smallcell lung cancer: past,present and future.Expert Rev Anticancer Ther 2013, 13:745-758.
5.Moyer VA,Force USPST.Screening for lung cancer: U.S.Preventive Services Task Force recommendation statement.Ann Intern Med 2014, 160:330-338.
6.Travis WD,Brambilla E,Nicholson AG,et al.The 2015 World Health Organization Classification of Lung Tumors: Impact of genetic,clinical and radiologic advances since the 2004 classification.J Thorac Oncol 2015, 10:1243-1260.
7.Travis WD,Brambilla E,Burke AP,et al.WHO Classification of Tumours of the Lung,Pleura,Thymus and Heart,Volume 7.Lyon:International Agency for Research on Cancer, 2015:412.
8.American College of Radiology.LungCT Screening Reporting and Data System(Lung-RADS), 2016.
9.MacMahon H,Naidich DP,Goo JM,et al.Guidelines for management of incidental pulmonary nodules detected on CT scans: from the Fleischner Society.Radiology 2017, 284:228-243.
10.Silvestri GA,Gonzalez AV,Jantz MA,et al.Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer,3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.Chest 2013, 143:e211S-250S.
11.Jordan EJ,Kim HR,Arcila ME,et al.Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies.Cancer Discov 2017, 7:596-609.(https://www.daowen.com)
12.Dugay F,Llamas-Gutierrez F,Gournay M,et al.Clinicopathological characteristics of ROS1- and.RETrearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations.Oncotarget 2017, 8:53336-53351.
13.Ou SI,Horn L,Cruz M,et al.Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.Lung Cancer 2017, 111:61-64.
14.Zakowski MF,Rekhtman N,Auger M,et al.Morphologic accuracy in differentiating primarylung adenocarcinoma from squamous cell carcinoma in cytology specimens.Arch Pathol Lab Med 2016, 140:1116-1120.
15.Goldstraw P,Chansky K,Crowley J,et al.The IASLC Lung Cancer Staging Project: Proposals for revision of the TNM stage groupings in the forthcoming(eighth)edition of the TNM classification for lung cancer.J Thorac Oncol 2016, 11:39-51.
16.Mazieres J,Zalcman G,Crino L,et al.Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: Results from the EUROS1 cohort.J Clin Oncol 2015, 33:992-999.
17.Ou SI,Ahn JS,De Petris L,et al.Alectinib in crizotinibrefractory ALK-rearranged non-small-cell lung cancer: a phase II global study.J Clin Oncol 2016, 34:661-668.
18.Douillard JY,Ostoros G,Cobo M,et al.First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV,open-label,single-arm study.Br J Cancer 2014, 110:55-62.
19.Planchard D,Besse B,Groen HJ,et al.Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutantmetastatic non-small cell lung cancer: an open-label,multicentre phase 2 trial.Lancet Oncol 2016, 17:984-993.
20.Klempner SJ,Borghei A,Hakimian B,et al.Intracranial activity of cabozantinib in MET exon 14-positive NSCLCwithbrainmetastases.J Thorac Oncol 2017, 12:152-156.
21.Sher DJ,Fidler MJ,Liptay MJ, et al.Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage III A non-small cell lung cancer.Lung Cancer 2015, 88:267-274.